Pouchitis

·MeSH: Pouchitis

Prevalence

30.0 / 100K

4 drugs in development·3 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
concomitant antibiotic therapy	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
concomitant antibiotic therapy	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 2(1)

Drug	Company
amt-101	Applied Molecular Transport Inc. (AMTI)

Phase 4(1)

Drug	Company
vedolizumab	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

BioSniper tracks 4 drugs in development for Pouchitis across 3 companies.

There are 2 clinical trials targeting Pouchitis tracked by BioSniper.

The estimated prevalence of Pouchitis is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.